Literature DB >> 8918490

Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early-stage testicular seminoma.

N N Sharda1, T J Kinsella, M A Ritter.   

Abstract

PURPOSE: This study was designed to compare costs of adjuvant radiation versus observation in the management of early-stage testicular seminoma after inguinal orchiectomy.
MATERIALS AND METHODS: A line-by-line inspection of the charges generated during a course of adjuvant pelvic and paraaortic radiotherapy and of three cycles of bleomycin, etoposide, and platinum salvage chemotherapy was performed for five patients who received irradiation and five patients who received salvage chemotherapy. The average charge for either treatment was then calculated. Only those charges directly associated with the diagnosis of seminoma were included in the analysis. Follow-up charges were also generated from the patients' billing records. The optimum follow-up regimen for either management option was derived from a synthesis of the international literature. A 5% rate of failure was assumed if adjuvant irradiation was administered, and a 15% rate of failure was assumed if observation was the option chosen. Charges were truncated at 5 years.
RESULTS: The total charge generated over 5 years based on following a policy of observation is $27,223 per patient versus $19,557 if the option of adjuvant irradiation in chosen. Using University of Wisconsin institutional reimbursement rates, the estimated costs were $20,487 and $14,722 for the option of observation and adjuvant radiation, respectively. The cost equivalence point between the two options occurs at 2.5 years, when the initial cost of adjuvant radiotherapy is matched by the cost generated during the period of observation. The maximum cost difference is achieved by 5 years.
CONCLUSION: Following a policy of observation postorchiectomy for early-stage testicular seminoma generates 39% more medical costs per patient over a 5-year follow-up period than does following the standard policy of adjuvant irradiation to the pelvic and paraaortic regions, with no reported difference in outcome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8918490     DOI: 10.1200/JCO.1996.14.11.2933

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

Review 1.  Testicular cancer: when less is more.

Authors:  Lance C Pagliaro
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

2.  Update on management of seminoma.

Authors:  Emma J Alexander; Ingrid M White; Alan Horwich
Journal:  Indian J Urol       Date:  2010 Jan-Mar

3.  What is the value of routine follow-up in stage I seminoma after paraaortic radiotherapy?: an analysis of the German Testicular Cancer Study Group (GTCSG) in 675 prospectively followed patients.

Authors:  Johannes Clasen; Heinz Schmidberger; Rainer Souchon; Lothar Weissbach; Michael Hartmann; Jörg T Hartmann; Thomas Hehr; Michael Bamberg
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

4.  Posttreatment surveillance after paraaortic radiotherapy for stage I seminoma: a systematic analysis.

Authors:  Johannes Classen; Rainer Souchon; Thomas Hehr; Michael Hartmann; Jörg T Hartmann; Michael Bamberg
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-14       Impact factor: 4.553

Review 5.  [Clinical stage I seminoma. Is surveillance a new therapy standard?].

Authors:  F Zengerling; J Müller; A J Schrader; M Schrader
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

Review 6.  Treatment of stage I testicular germ-cell tumors.

Authors:  Jorge Aparicio; J R Germà
Journal:  Med Oncol       Date:  2006       Impact factor: 3.738

Review 7.  Pure seminoma: a review and update.

Authors:  Noureddine Boujelbene; Adrien Cosinschi; Nadia Boujelbene; Kaouthar Khanfir; Shushila Bhagwati; Eveleyn Herrmann; Rene-Olivier Mirimanoff; Mahmut Ozsahin; Abderrahim Zouhair
Journal:  Radiat Oncol       Date:  2011-08-08       Impact factor: 3.481

8.  Cost analysis of adjuvant management strategies in early stage (stage I) testicular seminoma.

Authors:  John A Cox; Shefali R Gajjar; Thomas B Lanni; Todd A Swanson
Journal:  Res Rep Urol       Date:  2015-01-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.